Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

December 31, 2018

Study Completion Date

June 30, 2020

Conditions
Hyperparathyroidism; Secondary, Renal
Interventions
DRUG

Cinacalcet Tablets

All study subjects were treated with a fixed dose of oral Cinacalcet (25 mg/day) from baseline to 6 months.

DRUG

calcitriol

All hyperparathyroidism were treated as traditional therapy with oral calcitriol 0.25 mcg(dosage according to IPTH serum level) from baseline to 6 months.

Trial Locations (1)

Unknown

Min sheng general hospital, Taoyuan

All Listed Sponsors
collaborator

Taipei Medical University Shuang Ho Hospital

OTHER

collaborator

Taipei Medical University

OTHER

collaborator

En Chu Kong Hospital

OTHER

collaborator

National Taiwan University

OTHER

collaborator

Taichung Tzu Chi Hospital

OTHER

lead

Min-Sheng General Hospital

OTHER

NCT04637360 - Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment | Biotech Hunter | Biotech Hunter